Economical simulations for the optimal use of anti-programmed cell death-1 in advanced melanoma patients: Report of a budget impact analysis

J Oncol Pharm Pract. 2020 Jul;26(5):1216-1219. doi: 10.1177/1078155220918019. Epub 2020 Apr 20.

Authors

Justine Clarenne¹, Coralie Boulanger¹, Antonin Maréchal¹, Laëtitia Visseaux², Florian Slimano^{1

3}

Affiliations

¹ Department of Pharmacy, CHU Reims, Robert-Debré Hospital, Avenue du Général Koenig, 51092 Reims Cedex, France.
² Department of Dermatology, CHU Reims, Robert-Debré Hospital, Avenue du Général Koenig, 51092 Reims Cedex, France.
³ Faculty of Pharmacy, Reims University, 51 rue Cognacq-Jay, 51100 Reims, France.

PMID: 32312143
DOI: 10.1177/1078155220918019

No abstract available

Keywords: Melanoma; healthcare financing; nivolumab; pembrolizumab.